JPMorgan Chase & Co. Has $864,000 Stock Holdings in UroGen Pharma Ltd. (NASDAQ:URGN)

JPMorgan Chase & Co. lifted its holdings in shares of UroGen Pharma Ltd. (NASDAQ:URGNFree Report) by 263.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 68,062 shares of the company’s stock after buying an additional 49,318 shares during the period. JPMorgan Chase & Co. owned about 0.29% of UroGen Pharma worth $864,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. lifted its stake in UroGen Pharma by 90.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company’s stock valued at $103,000 after acquiring an additional 3,856 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in UroGen Pharma by 221.8% during the third quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock worth $109,000 after purchasing an additional 5,890 shares during the period. Intech Investment Management LLC bought a new stake in UroGen Pharma in the third quarter valued at approximately $155,000. Verition Fund Management LLC bought a new position in shares of UroGen Pharma during the 3rd quarter worth approximately $168,000. Finally, SG Americas Securities LLC acquired a new position in shares of UroGen Pharma during the 3rd quarter worth approximately $179,000. 91.29% of the stock is owned by institutional investors and hedge funds.

UroGen Pharma Price Performance

URGN stock opened at $10.24 on Friday. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. UroGen Pharma Ltd. has a 52-week low of $9.78 and a 52-week high of $20.70. The company has a market capitalization of $240.17 million, a P/E ratio of -3.25 and a beta of 1.09. The company has a fifty day moving average price of $11.20 and a 200-day moving average price of $12.95.

UroGen Pharma (NASDAQ:URGNGet Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.29. The company had revenue of $25.20 million for the quarter, compared to the consensus estimate of $24.22 million. During the same period in the prior year, the business earned ($0.68) earnings per share. As a group, equities analysts expect that UroGen Pharma Ltd. will post -3.1 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently commented on URGN. Oppenheimer reaffirmed an “outperform” rating and set a $40.00 target price on shares of UroGen Pharma in a report on Wednesday, October 16th. D. Boral Capital reissued a “buy” rating and set a $25.00 price target on shares of UroGen Pharma in a report on Thursday. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price objective on shares of UroGen Pharma in a report on Tuesday, October 15th. Finally, EF Hutton Acquisition Co. I raised UroGen Pharma to a “strong-buy” rating in a report on Monday, October 14th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $43.70.

Check Out Our Latest Analysis on URGN

About UroGen Pharma

(Free Report)

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

Read More

Institutional Ownership by Quarter for UroGen Pharma (NASDAQ:URGN)

Receive News & Ratings for UroGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UroGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.